Clinical Trial Search

Primary: Short-latency Afferent Inhibition — 48; 21 % of unconditioned motor evoked potentia

Primary: Response Rate — 4 Participants

Primary: Proportion of Participants Who Experience Worsening of Asthma by Week 24 — 0.658; 0.567; 0.568; 0.557 proportion of participants — p=0.1425

Primary: Cystine Capacity — 43.1 mg/L

Primary: Core Treatment Phase: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 12 Based on Non-responder Imputation (NRI)…

Primary: Number of Leads With Electrical Dysfunction — 24; 27; 15; 2 implanted leads

Primary: Number of Participants Whose Ablation Resulted in Technical Success — 30; 30 Participants

Primary: Mean Plasma L-ascorbic Acid as Total Area Under the Curve [AUC(0-24 Hours)] — 1114.66; 1149.09 μmol*min/L

Primary: Change in Testosterone Levels From Baseline to 27 Weeks — 652 ng/dL

Primary: Percentage of Participants Who Died — 0; 0; 0; 0 percentage of participants

Primary: NFC Blood Flow at Baseline and 15 Minutes — 72.52; 83.94; 93.01; 60.50 pL/s

Primary: Incidence of First Occurrence of Adjudication-confirmed Narrowly Defined MACE — 34; 42; 76; 92 events — p=0.1070

Primary: Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Ecarin Clotting Time — 100.0; 100.0; 100.0 Percentage

Primary: Number of Recruited Providers That Contact Staff for Information About Enrolling in the Study — 36; 36; 44; 44 Participants

Primary: Annual Rate of Occurrence of Serious Bacterial Infections (SBI) — 0; 0.01; 0; 0.03 Rate of events per subject per year